Ana Pena, PhD,  —

The European Patent Office (EPO) has issued a “notice of intent” to grant a patent to MN-001 (tipelukast), MediciNova’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF). Once issued, the patent will…

Female sex, younger age, and a better lung function at time of diagnosis tend to support a a better overall prognosis among people with idiopathic pulmonary fibrosis (IPF), a large registry-based study reports. In contrast, the presence of pulmonary hypertension (PH), lung cancer,…

Overactivation of a protein called mucin 1 (MUC1) triggers pro-fibrotic transformations in the lungs that could contribute to the development and progression of idiopathic pulmonary fibrosis (IPF), an early study using patient cells and mice has found. The research furthers knowledge about the roles played by MUC1-induced pathways,…

miRagen Therapeutics is reshaping its strategy to focus on the development of MRG-229, a potential treatment for idiopathic pulmonary fibrosis (IPF). The company expects to share new efficacy and safety preclinical data on MRG-229 during the…

Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis (IPF), will start in the coming weeks, Genkyotex announced in a progress report. Following approval by the U.S. Food and Drug Administration (FDA) in July, the study protocol now…

A metabolic process called the mevalonate pathway may be a promising therapeutic target to fight idiopathic pulmonary fibrosis (IPF), according to an early research study using mouse models and lung fluid collected from IPF patients. Researchers also suggest that lung injury may not be as key…

MUC5B genetic variants and shorter telomeres — or chromosome endings — are risk factors associated with greater lung damage and poorer survival in Chinese patients with idiopathic pulmonary fibrosis (IPF), a study has revealed. The study, “The relationship between MUC5B promoter, TERT polymorphisms and telomere…

A genetic variant at the IFNL3 gene is linked to raised levels of IFN-lambda 3 in the blood and is associated with the presence of pulmonary fibrosis in patients with systemic sclerosis, but it does not represent a risk factor for worsening of skin fibrosis in these patients, a…

Veracyte announced new data further supporting its Envisia Genomic Classifier as a useful tool in helping doctors to diagnosis idiopathic pulmonary fibrosis (IPF) with greater confidence and without the need for surgery to biopsy lung…

Healthy and idiopathic pulmonary fibrosis (IPF) lung cells respond differently to transforming growth factor-beta 1 (TGF-beta 1) — a key mediator of fibrosis — both in terms of gene activity and DNA methylation, likely due to the fibrotic environment that IPF cells are exposed to in the lungs,…